| Code | CSB-RA004929MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to CID-103, targeting CD38, a type II transmembrane glycoprotein that functions as both an ectoenzyme and a receptor. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and ADP-ribose from NAD+, playing crucial roles in calcium signaling, cell adhesion, and signal transduction. This protein is widely expressed on various immune cells, including plasma cells, activated T cells, B cells, and natural killer cells. CD38 has emerged as a significant therapeutic target due to its high expression in multiple myeloma and other hematological malignancies, as well as its involvement in inflammatory disorders and immune regulation.
CID-103 serves as the reference antibody for this biosimilar product, providing researchers with a cost-effective alternative for investigating CD38 biology and function. This antibody is particularly valuable for studies examining plasma cell biology, B cell development, immune cell activation, and the pathophysiology of hematological cancers. It supports research into CD38-mediated signaling pathways and immune cell interactions in various disease contexts.
There are currently no reviews for this product.